Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | PKLR | P30613 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | COMT | P21964 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6616459 | 0.98 | TSHR (0.56) | PKMPKLRTSHRCYP3A4CYP2C9 | |
| SCHEMBL6559920 | 0.85 | PKM (0.44) | PKMPKLRTSHRCYP3A4CYP2C9 | |
| SCHEMBL4708071 | 0.84 | PKM (0.59) | PKMPKLRTSHRKDM4EALDH1A1 | |
| SCHEMBL12655896 | 0.84 | PKM (0.52) | PKMPKLRTSHRCYP3A4CYP2C9 | |
| SCHEMBL14040701 | 0.83 | PKM (0.46) | PKMPKLRTSHRCYP3A4CYP2C9 | |
| SCHEMBL24712032 | 0.82 | PKM (0.50) | PKMPKLRTSHRKDM4ENPC1 | |
| SCHEMBL2962440 | 0.82 | ALDH1A1 (0.59) | PKMPKLRALDH1A1GAASMN1; SMN2 | |
| SCHEMBL10272543 | 0.80 | NPSR1 (0.52) | PKMPKLRTSHRKDM4EALDH1A1 | |
| SCHEMBL5093011 | 0.80 | PKM (0.43) | PKMPKLRTSHRCYP3A4CYP2C9 | |
| SCHEMBL13341692 | 0.80 | PKM (0.43) | PKMPKLRTSHRCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321011-A1 | DIARYL COMPOUNDS AND USES THEREOF | Pfizer Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20100035873-A1 | Diaryl Compounds and Uses Thereof | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| WO-2009156889-A1 | DIARYL COMPOUNDS AND USES THEREOF | PFIZER INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035873-A1 | Diaryl Compounds and Uses Thereof | OPRK1, OPRD1, OPRL1 | PKM 1372/4885PKLR 1190/4885TSHR 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.